Table 2 Laboratory findings of COVID-19 patients with cardiac injury.
From: Key factors leading to fatal outcomes in COVID-19 patients with cardiac injury
Characteristic | Median (IQR) | |||
|---|---|---|---|---|
Total (N = 173) | Nonsurvivors (N = 87) | Survivors (N = 86) | p value | |
Blood routine | ||||
Leukocyte count, × 109/L | 7.18 (4.83–11.09) | 8.88 (5.11–12.79) | 6.68 (4.70–8.83) | .005 |
Neutrophil count, × 109/L | 5.72 (3.73–9.52) | 7.41 (4.18–11.49) | 4.97 (3.30–6.95) | .001 |
Lymphocyte count, × 109/L | 0.7 (0.45–0.98) | 0.54 (0.36–0.83) | 0.76 (0.62–1.11) | .001 |
Monocyte count, × 109/L | 0.40 (0.26–0.55) | 0.40 (0.25–0.53) | 0.40 (0.28–0.61) | .512 |
Platelet count, × 109/L | 172 (118–217) | 151 (93–206) | 192.50 (146.50–227.25) | .001 |
Hemoglobin, g/L | 125 (109–137) | 129 (114–138) | 123.50 (105.75–136.25) | .270 |
Coagulation function | ||||
Prothrombin time, s | 12.70 (11.90–13.60) | 12.90 (12.07–14.30) | 12.50 (11.80–13.02) | .004 |
Activated partial thrombin time, s | 29.1 (26.30–32.77) | 29.60 (27.85–33.82) | 28.50 (25.80–31.70) | .006 |
D-dimer, mg/L | 2.86 (0.90–15.71) | 4.33 (1.22–19.15) | 1.72 (0.82–11.70) | .003 |
Blood biochemistry | ||||
Albumin, g/L | 33.40 (31.60–37.00) | 33.40 (31.55–36.05) | 33.40 (31.57–37.22) | .388 |
Creatine kinase, U/L | 90.00 (51.00–241.00) | 104 (57.00–379.50) | 80.50 (47.75–161.25) | .355 |
Lactate dehydrogenase, U/L | 428.5 (287.25–589.00) | 499 (372.25–726.25) | 362 (260.50–491.75) | < .001 |
Alanine aminotransferase,U/L | 27.00 (18.00–45.00) | 26.00 (19.0–40.50) | 29.00 (17.50–51.25) | .286 |
Aspartate aminotransferase,U/L | 41.00 (27.00–59.00) | 47.00 (28.00–70.00) | 36.50 (23.75–52.50) | .961 |
Total bilirubin, μmol/L | 12.80 (8.70–18.30) | 14.10 (9.10–22.15) | 11.15 (8.60–15.72) | .009 |
Blood urea nitrogen, mmol/L | 7.70 (5.10–13.90) | 9.36 (5.81–16.50) | 6.75 (4.54–9.37) | .002 |
Serum creatinine, μmol/L | 69.00 (55.00–112.00) | 76.00 (54.50–127.00) | 67.00 (54.25–94.50) | .627 |
Hypersensitive troponin I, ng/mL | 0.15 (0.69–0.75) | 0.69 (0.15–2.60) | 0.079 (0.056–0.15) | < .001 |
N-Terminal pro-brain natriuretic peptide (NT-proBNP), pg/ml | 855.50 (298.50–2560.00) | 1144 (475.55–3119.50) | 615.90 (217.95–2027.25) | 1.000 |
C-reactive protein, mg/L | 71.40 (37.80–148.50) | 101.00 (52.72–187.42) | 59.10 (30.60–108.60) | < .001 |
Procalcitonin, ng/mL | 0.174 (0.083–0.637) | 0.405 (0.119–1.365) | 0.103 (0.063–0.251) | .007 |
CD4 count, μl−1 | 205 (128–353) | 164 (104.5–280.5) | 290 (174–422) | < .001 |
CD8 count, μl−1 | 114 (59–212) | 75.50 (51.25–142.75) | 156.00 (83.00–233.0) | .002 |
CD4/CD8 | 1.82 (1.17–2.91) | 1.77 (1.11–2.86) | 1.99 (1.20–3.99) | .844 |
IL-6, pg/ml | 41.39 (12.25–147.63) | 95.85 (40.42–605.96) | 15.81 (6.35–36.00) | < .001 |
Tumor necrosis factors(TNFα), pg/ml | 3.405 (2.91–4.76) | 3.68 (2.82–4.88) | 3.35 (2.92–4.76) | .383 |
